H. Pöhlmann

1.9k citations

19 papers · 1.5k indexed · h-index 14

Impact in

Psychiatry and Mental health top 2%
- Epilepsy research and treatment
Pediatrics, Perinatology and Child Health top 2%
- Pharmacological Effects and Toxicity Studies
- Pharmaceutical studies and practices

Papers in

Psychiatry and Mental health 5
- Epilepsy research and treatment 3
- Attention Deficit Hyperactivity Disorder 2
Pathology and Forensic Medicine 5
- Multiple Sclerosis Research Studies 4

Co-authors: Alan Moore Ludwig Kappos Xavier Montalbán Jack P. Antel Paul O’Connor Maria Luíza Giraldes de Manreza Sérgio Antônio Antoniuk Natalio Fejerman
Journals: Neurology (5 papers)Epilepsy Research (3 papers)The Lancet Neurology (2 papers)Multiple Sclerosis and Related Disorders (1 paper)Pediatric Drugs (1 paper)
Partner nations: Switzerland Germany United States

In The Last Decade

H. Pöhlmann

18 papers receiving 1.4k citations

Peers

Countries citing papers authored by H. Pöhlmann

Since Specialization

Citations

This map shows the geographic impact of H. Pöhlmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Pöhlmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Pöhlmann more than expected).

Fields of papers citing papers by H. Pöhlmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Pöhlmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Pöhlmann. The network helps show where H. Pöhlmann may publish in the future.

Co-authorship network

The 25 scholars most cited alongside H. Pöhlmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Pöhlmann Line = papers co-authored together H. Pöhlmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis Neurology ·Ralph H. B. Benedict, Davorka Tomic, Bruce Cree, Robert J. Fox, Gavin Giovannoni, Amit Bar‐Or, Ralf Gold, Patrick Vermersch, H. Pöhlmann, Ian M. Wright, Göril Karlsson, Frank Dahlke, Christian Wolf, Ludwig Kappos	2021	60
2	Blinded sample size reestimation in event‐driven clinical trials: Methods and an application in multiple sclerosis Pharmaceutical Statistics ·Tim Friede, H. Pöhlmann, Heinz Schmidli	2019	11
3	Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study (S44.004) Neurology ·Ralph H. B. Benedict, Bruce Cree, Davorka Tomic, Robert J. Fox, Gavin Giovannoni, Amit Bar‐Or, Ralf Gold, Patrick Vermersch, H. Pöhlmann, Göril Karlsson, Frank Dahlke, Ludwig Kappos	2018	6
4	Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial Multiple Sclerosis and Related Disorders ·Ludwig Kappos, Amit Bar‐Or, Bruce Cree, R. H. Fox, Gavin Giovannoni, Ralf Gold, P. Vermersch, Elaine T. Lam, H. Pöhlmann, Erik Wallström	2014	11
5	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study The Lancet Neurology ·Krzysztof Selmaj, David K.B. Li, Hans-Peter Hartung, Bernhard Hemmer, Ludwig Kappos, Mark S. Freedman, Olaf Stüve, Peter Rieckmann, Xavier Montalbán, Tjalf Ziemssen, Lixin Zhang Auberson, H. Pöhlmann, François Mercier, Frank Dahlke, Erik Wallström	2013	185
6	BAF312, a Selective Sphingosine-1-Phosphate Receptor Modulator Improves MRI and Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (RRMS) (S30.001) Neurology ·Olaf Stüve, Krzysztof Selmaj, Francisco Ferreira da Silva, HP Hartung, Bernhard Hemmer, Ludwig Kappos, Mark Freedman, Peter Rieckmann, Xavier Montalbán, Lixin Zhang Auberson, H. Pöhlmann, François Mercier, Frank Dahlke, Erik Wallström	2012	1
7	Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results Multiple Sclerosis Journal ·Cristoforo Comi, Paul O’Connor, Xavier Montalbán, Jack P. Antel, Ernst W. Radue, Goeril Karlsson, H. Pöhlmann, Shreeram Aradhye, Ludwig Kappos, Wu Xiaoshu	2009	121
8	Oral fingolimod (FTY720) in multiple sclerosis Neurology ·Paul O’Connor, Giancarlo Comi, Xavier Montalbán, Jack P. Antel, EW Radue, Ana de Vera, H. Pöhlmann, Ludwig Kappos	2009	149
9	Phase II/III randomized trial of TCH346 in patients with ALS Neurology ·Robert G. Miller, Walter G. Bradley, Merit Cudkowicz, Jean Hubble, Vincent Meininger, Hiroshi Mitsumoto, Dan H. Moore, H. Pöhlmann, D. Sauer, Vincenzo Silani, Michael J. Strong, Michael Swash, I. I. Hancock, (unknown)	2007	88
10	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial The Lancet Neurology ·C. Warren Olanow, Anthony H.V. Schapira, Peter A. LeWitt, Karl Kieburtz, Dirk Sauer, Gianfranco Olivieri, H. Pöhlmann, Jean Hubble	2006	121
11	Efficacy and Safety of Ritalin?? LA???, a New, Once Daily, Extended-Release Dosage Form of Methylphenidate, in Children with Attention Deficit Hyperactivity Disorder Pediatric Drugs ·Joseph Biederman, Declan Quinn, Margaret D. Weiss, S. Markabi, Meredith Weidenman, Bárbara Soto Neira, Goeril Karlsson, H. Pöhlmann, Sharon B. Wigal	2003	81
12	Advanced Head and Neck Cancer: Long-Term Results of Chemo-Radiotherapy, Complications and Induction of Second Malignancies Oncology Research and Treatment ·Reinhold Munker, 钱思宇, Ü. Aydemir, Yves Barel, H. Pöhlmann, Iseul Na, R. Hartenstein	2001	10
13	A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy Epilepsy Research ·Gastón Fazio, Brahim Labari, H. Pöhlmann, Carlos A.M. Guerreiro, Silvia Kochen, D Saffer, Alan Moore	1997	165
14	A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy Epilepsy Research ·W. Christe, Günter Krämer, Brahim Labari, H. Pöhlmann, Bernhard J. Steinhoff, Martin J. Brodie, Alan Moore	1997	170
15	A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy Epilepsy Research ·Marilisa M. Guerreiro, Brahim Labari, H. Pöhlmann, Maria Luíza Giraldes de Manreza, Natalio Fejerman, Sérgio Antônio Antoniuk, Alan Moore	1997	193
16	A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression Journal of Affective Disorders ·G Chouinard, A. L. Kavunnyk, N.P.V. Nair, Stan Kutcher, David Bakish, Jacques Bradwejn, Sidney H. Kennedy, N. Jayashree, Ronald A. Remick, Lijun Guo, Marie–Claire Bélanger, Veronika Karácsony, Linda Beauclair, H. Pöhlmann, J. D’Souza	1994	13
17	Geostatistical modelling of environmental data CATENA ·H. Pöhlmann	1993	18
18	Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs Annals of Hematology ·W. Schramm, Michael Roggendorf, Felix Rommel, Robert Kammerer, H. Pöhlmann, Eric Nathaniel Pena, R. Kim, Friedrich Deinhardt	1989	33
19	Radiological evaluation of chronic hemophilic arthropathy by the Pettersson score: problems in correlation in adult patients Skeletal Radiology ·J. F. Hamel, H. Pöhlmann, W. Schramm	1988	22

About H. Pöhlmann

H. Pöhlmann is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine, Otorhinolaryngology, Hematology and Pediatrics, Perinatology and Child Health, having authored 19 papers that have together received 1.5k indexed citations. Recurring topics across this work include Sphingolipid Metabolism and Signaling (5 papers), Multiple Sclerosis Research Studies (4 papers), Phytochemistry and Biological Activities (4 papers), Epilepsy research and treatment (3 papers), Pharmacological Effects and Toxicity Studies (3 papers), Attention Deficit Hyperactivity Disorder (2 papers), Drug Transport and Resistance Mechanisms (2 papers) and Research on Leishmaniasis Studies (2 papers). The work is most often cited by research in Psychiatry and Mental health (591 citations), Pediatrics, Perinatology and Child Health (511 citations), Pathology and Forensic Medicine (353 citations), Neurology (287 citations) and Cellular and Molecular Neuroscience (284 citations). H. Pöhlmann has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Alan Moore, Ludwig Kappos, Xavier Montalbán, Jack P. Antel, Paul O’Connor, Maria Luíza Giraldes de Manreza, Sérgio Antônio Antoniuk, Natalio Fejerman, Marilisa M. Guerreiro and D Saffer. Their work appears in journals such as Neurology, Epilepsy Research, The Lancet Neurology, Multiple Sclerosis and Related Disorders and Pediatric Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact